Pfizer Records Largest Quarterly Sales in Q2 2022 Fueled by COVID-19 Vaccine and Paxlovid Sales
Both COVID-19 sales and Paxlovid contributed immensely to the impressive financial report Pfizer announced for Q2 2022.
PFE Stock Down 3%, Pfizer Reports Better-than-Expected Q4 2021 Earnings and Raises Full-Year Sales Forecast for Covid Vaccine
PFE stock has had mixed volatility in the past year, up approximately 47.84% in the past year but down approximately 12.45% YTD.
PFE Stock Slightly Up, Pfizer CEO Says Omicron Vaccine to Be Ready in March
Pfizer CEO said that it is not clear if a fourth dose is required. He explained that Pfizer would conduct experiments to reach a conclusion.
PFE Stock Slightly Down, Pfizer Begins Large Study of Oral Drug for Covid Prevention
The PF-07321332 drug will be administered alongside a low dose of Ritonavir, a widely used drug in HIV treatment.
What’s Next for PFE Stock as Pfizer CEO Predicts Back to Normal Life in One Year
Pfizer stock has gained approximately 28%, 19%, and 12% in the past year, YTD, and three months respectively through last Friday.
PFE Stock Rebounds, Pfizer Covid Vaccine Safe for Kids, Covid Is Officially America’s Deadliest Pandemic
By
Darya Rudz
Pfizer will submit the data received to the Food and Drug Administration (FDA) and other health regulators “as soon as possible.” However, it is unclear how much time the authorities will need to review the data and approve the vaccine.
Pfizer and Moderna COVID-19 Vaccines Proves Effective in Real-World Use after First Shot
The potential efficacy in the approved Pfizer-BioNTech and Moderna vaccines is spurring a delay in second dose administration by some nations, especially those with limited supplies of the jabs.
PFE Stock Down 2%, Pfizer Reports Profitable Q4, Works on Adapting Vaccine to New Strains
Pfizer raised its earnings guidance for the 2021 fiscal year noting that its revenues will range between $59.4 billion and $61.4 billion, with vaccine sales taking a prominent role in the achievement.
Pfizer-BioNTech Vaccine Is Efficient Against UK COVID Variant, PFE Stock Slightly Up
The vaccine from the duo of Pfizer-BioNTech as well as Moderna is expected to fetch the firms as much as $15 billion in sales by the year 2023.
PFE Stock Down 1.7%, US Government and Pfizer Near Conclusion on Vaccine Negotiation
By
John K. Kumi
Pfizer requires the government to give them access to about nine specialized products which is said to include Lipids, and this can be done by invoking the defense production act.
PFE Stock Rises on FDA Authorization Pfizer COVID-19 Vaccine for Emergency Use, US to Immunize 100 Million by End of March
By
Darya Rudz
According to the FDA, Pfizer’s COVID-19 vaccine is given as two shots administered 21 days apart. One dose is to prime the body, and then a few weeks later, the second dose is to boost the response.
Pfizer (PFE) Vaccine Now Administered in UK, First Person Gets Vaccine Outside Trial
While the Pfizer (PFE) vaccine is the first of the vaccines expected to get regulatory approval this year, its distribution may be limited considering its extremely low storage and distribution temperature of minus 70 degrees Celsius and below.
PFE Stock Down 2% Now, Pfizer Launches COVID-19 Vaccine Delivery Trial in US
Pfizer noted that the decision to conduct the vaccine delivery trial was based on the uniqueness of each state because of their size, existing immunization infrastructure, diversity in the population and other factors.
Pfizer CEO Sells 60% of His PFE Stock after COVID-19 Vaccine Proved to Be 90% Effective
By
Darya Rudz
On the same day when Pfizer announced the results of the vaccine trial, the company’s CEO Albert Bourla sold 132,508 shares (or 62% of his stock) at the price of $41.99.
Pfizer COVID-19 Vaccine Efficacy Spurs Market Surge
Following the positive news about the Pfizer COVID-19 vaccine efficacy, the stock market has responded with big jumps.